Mucopolysaccharidosis I - 56 Studies Found Completed : Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase : Hunter Syndrome Mucopolysaccharidosis II< : 2008-02-28 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly Completed : Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome : Hunter Syndrome : 2011-10-06 : Other: No treatment Completed : Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy : Hunter Syndrome Mucopolysaccharidosis II< : 2008-01-22 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg weekly Completed : An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients : Hunter Syndrome : 2009-04-16 : Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally Completed : A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® : Hunter Syndrome : 2009-06-12 : Other: Control 3 dose cohorts Enrolling by invitation : Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 : Hunter Syndrome : 2015-04-01 : Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m Completed : Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® : Hunter Syndrome : 2009-07-09 : Behavioral: Neurobehavioral testing Active, not recruiting : Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment : Hunter Syndrome : 2014-01-17 : Biological: idursulfase-IT 10m Active, not recruiting : Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment : Hunter Syndrome : 2011-12-15 : Drug: Idursulfase-IT Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via Completed : Safety and Efficacy of Hunterase : Hunter Syndrome : 2012-07-16 : Biological: Hunterase once weekly, 0.5mg/kg IV infusion <<< Previous | Next >>>
